Search

The main predictor of a child with attention‐deficit/hyperactivity disorder (ADHD) being prescribed psychotropic medications in addition to stimulants is a psychiatric consultation, according to a new study from Canada. Researchers looked at children in Ontario to determine the predictors of medication prescription for ADHD in youth, as well as the prevalence and characteristics of youth with ADHD. [ABSTRACT FROM AUTHOR]

The article presents study investigating the benefits of adding a drug risperidone to initial treatment with a stimulant in preadolescent nonresponders with attention-deficit/ hyperactivity disorder (ADHD), disruptive behavior disorders, and severe aggression. It is mentioned that combination treatment offers fewer side effects than with either drug used alone.

There are no known pharmacotherapies for autism spectrum disorder (ASD); however, clinicians commonly prescribe psychotropic medication for behaviors and symptoms associated with ASD. Researchers conducted a review of studies looking at which medications work for what behaviors and symptoms. [ABSTRACT FROM AUTHOR]

The article discusses a study which examines the effectiveness of a therapy augmented with risperidone in children with attention-deficit hyperactivity disorder (ADHD) or oppositional defiant disorder (ODD) based on parent and teacher ratings. Findings reveal that parent and teacher ratings have different assessments about the capacity of the therapy to reduce ADHD and ODD symptoms. The discrepancy in the ratings is caused by the challenges associated to the identification of the diseases.

The article presents a research review that found no evidence in supporting the use of the antiseptic medication risperidone for the treatment of attention-deficit/hyperactivity disorder (ADHD).It mentions the of two studies where no indluded because they did not separate the result for a subgroup with the co-occurring ADHD and intellectual disabilities. It emphasizes that resperindone should not be the first-line treatment for ADHD.

The article discusses the site characteristics in comparing the efficacy between risperidone and lithium in patients wiithout attention-deficit hyperactivity disorder (ADHD).

The article offers updates from the U.S. Food and Drug Administration (FDA) on psychopharmacology-related drug approvals including the first generic version of Lexapro, lisdexamfetamine capsules of Shire Pharmaceuticals Group PLC, and labeling revisions for donepezil, ramelteon and ketamine.

The article presents a case study of an 11-year-old boy with attention-deficit/hyperactivity disorder (ADHD) who was referred because of hyperactivity, anger, aggression and inattention. Atomoxetine was started to the patient, resulting in improved concentration and attention but with no effect on hyperactivity. He also received risperidone but the patient experienced painless, frequent penile erections. He continued to have penile erections, but fully recovered when the drug was stopped.

The article presents three case reports of children with attention-deficit hyperactivity disorder (ADHD) who developed severe adverse reactions of risperidone to methylphenidate switch. A five year old male suffered from severe behavioral reactions after the drug switching. Another is a six-year-old female who discontinued her risperidone medication. Another 15-year-old female suffered from agitation, irritability and discomfort after the drug switching.

The article cites a study where a 28-day, single-blind, randomized trial compared the efficacy and tolerability of risperidone and methylphenidate (MPH) to reduce symptoms of attention deficit hyperactivity disorder (ADHD) in children and adolescents with moderate mental retardation (MMR). Study results, published in "JAACAP," suggest that while both medications are effective in reducing ADHD symptoms, risperidone may have a more pronounced effect. Each medication had a unique side effect profile that could be important in choosing between the two. Subjects for this parallel-group trial included children and adolescents ages 6 to 16 with diagnoses of both MMR and ADHD according to DSM-IV criteria.